Docetaxel and other DNA-damaging chemotherapies reliably induce cellular senescence in prostate cancer cells, but the resulting senescence-associated secretory phenotype (SASP) contains ECM-remodeling factors—alongside inflammatory cytokines—that paradoxically facilitate tumor cell dissemination. In syngeneic murine prostate cancer models, docetaxel reduced primary tumor growth yet failed to activate anti-tumor immunity or restrain metastasis. Adding senolytics targeting BCL2 and IAP pro-survival pathways—upregulated in senescent tumor cells post-docetaxel—selectively cleared those cells, remodeled the SASP, repolarized myeloid populations, and potentiated CD8+ T cell activation, collectively suppressing metastatic spread.
This finding reframes a longstanding clinical paradox: docetaxel extends survival in metastatic prostate cancer but rarely achieves durable remission, and therapy-induced senescence has long been a suspected culprit in disease relapse. By demonstrating that senolytic clearance converts an immunosuppressive SASP into an immunostimulatory one, the work provides a mechanistic rationale for combining navitoclax-class BCL2 inhibitors or Smac mimetics with standard chemotherapy regimens. That logic is plausible: both drug classes already have clinical-stage data in hematologic and solid tumors. Limitations are notable—findings rest on cell lines and mouse models, and SASP composition is notoriously species- and context-dependent, meaning human tumor microenvironments may respond differently. Still, this is more than incremental: it offers a testable, mechanism-driven combination strategy with immediate translational hooks for ongoing prostate cancer trials.
